WuXi AppTec IPO Valuation: Not Much Money Left on the Table
WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....
592 Views
Wuxi Apptec 药明康德 IPO: Welcome to the A/H Universe
WuXi Apptec is set to be the newest A/H pair with its upcoming HK listing that is set to raise USD 1 billion. The A-share (603289 CH) recorded 15...
830 Views
The Week That Was in NorthAsia@Smartkarma: NK Nuke, Topix, Nikkei 225, & HHI Recapitalization
Below is the full list of Japan/Korea related reports published last week on Smartkarma.TOPIX inclusion eventTravis touched on the stocks to be...
191 Views
New Stem Cell Treatment for Parkinsons Positive for Catalent and Eisai
A pioneering new stem cell treatment with the 'potential to cure Parkinson's disease' has been crafted by researchers. In trials on laboratory...
175 Views
WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China
WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares. Proceeds will be used...
766 Views